Cite
Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis.
MLA
Flörsch, Benedikt, et al. “Treatment Patterns and Prognosis of Patients with Inoperable Stage III NSCLC after Completion of Concurrent Chemoradiotherapy ± Immune Checkpoint Inhibition: A Decade-Long Single-Center Historical Analysis.” Journal of Cancer Research & Clinical Oncology, vol. 149, no. 7, July 2023, pp. 3267–76. EBSCOhost, https://doi.org/10.1007/s00432-022-04174-z.
APA
Flörsch, B., Taugner, J., Käsmann, L., Kenndoff, S., Guggenberger, J., Tufman, A., Reinmuth, N., Duell, T., Belka, C., Eze, C., & Manapov, F. (2023). Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis. Journal of Cancer Research & Clinical Oncology, 149(7), 3267–3276. https://doi.org/10.1007/s00432-022-04174-z
Chicago
Flörsch, Benedikt, Julian Taugner, Lukas Käsmann, Saskia Kenndoff, Julian Guggenberger, Amanda Tufman, Niels Reinmuth, et al. 2023. “Treatment Patterns and Prognosis of Patients with Inoperable Stage III NSCLC after Completion of Concurrent Chemoradiotherapy ± Immune Checkpoint Inhibition: A Decade-Long Single-Center Historical Analysis.” Journal of Cancer Research & Clinical Oncology 149 (7): 3267–76. doi:10.1007/s00432-022-04174-z.